Synergistic Notch-WNT Activation Underlies Pediatric Dilated Cardiomyopathy

This study identifies the pathological co-activation of developmental Notch and WNT signaling pathways as a unique driver of myocardial stiffening and dysfunction in pediatric dilated cardiomyopathy, demonstrating that inhibiting this axis improves cardiac function and supporting the need for age-specific therapeutic strategies distinct from adult heart failure treatments.

The Gist

The Big Picture: Why Kids' Hearts Are Different

Imagine the human heart as a car engine. For decades, doctors have treated sick engines in children using the same repair manuals used for sick engines in adults. They give the same medicines, assuming a broken heart is a broken heart, no matter the age.

However, this study suggests that children's hearts break differently than adults' hearts.

• Adult Heart Failure: Think of this like an old engine that has rusted, developed cracks, and is covered in thick sludge (fibrosis/scarring). The engine is stiff because it's clogged with damage.
• Children's Heart Failure: This is different. The engine isn't rusty or clogged with sludge. Instead, the computer chip inside the engine has accidentally rebooted an old, factory-installed "childhood mode" program that was supposed to be deleted after birth. This program is trying to build a heart from scratch, but since the heart is already built, it just makes things stiff and weak.

The Culprits: Two "Construction Managers" Gone Wild

The study found two specific signaling pathways (think of them as construction managers) that are usually quiet after a baby is born but get turned on in sick children:

1. Notch: A manager that usually helps cells talk to each other during development.
2. WNT: A manager that helps cells grow and change shape during development.

In a healthy adult heart, these managers are retired. In the sick children studied, these two managers were working overtime together, shouting orders that confused the heart cells. They told the cells to act like they were still growing, which made the heart muscle stiff and unable to pump blood effectively.

The Experiment: Recreating the Chaos in the Lab

To prove this theory, the scientists created a "mini-heart" model using young rats. They wanted to see if they could trigger this specific "childhood mode" by mixing two things found in sick children:

• Stress Hormones (Isoproterenol): Like revving an engine too hard.
• A specific protein (sFRP1): A chemical signal that was found to be high in the blood of children with heart failure.

The Result: When they gave the rats both the stress hormone and the protein, the rats' hearts developed the exact same problems as the sick children:

• The heart chambers got big and floppy (dilation).
• The pumping power dropped.
• The heart muscle got stiff (like a rubber band that lost its snap).
• Crucially: There was no rust or sludge (no scarring/fibrosis). It was pure "software" confusion, not "hardware" damage.

The "Stiffness" Mystery

One of the most surprising findings was about stiffness.
Imagine a sponge.

• A healthy sponge is soft and squishy.
• A scarred adult heart is like a sponge filled with concrete (hard because of damage).
• A sick child's heart in this study was like a sponge that had been soaked in super-glue. It wasn't filled with concrete, but the material itself had become rigid.

The study found that the "Notch-WNT" managers were causing the heart cells to become stiff, which stopped them from stretching and squeezing properly. This stiffness happened without any scarring, which is why adult heart medicines (which usually try to stop scarring) don't work well for these kids.

The Solution: Hitting the "Pause" Button

The researchers then tried to stop these two managers from working. They used a drug called DAPT, which acts like a "mute button" for the Notch manager.

What happened?

• The "childhood mode" program shut down.
• The heart muscle became soft and flexible again.
• The heart started pumping blood much better.

This proves that if you can turn off these specific developmental signals, you can actually fix the heart's function in this specific type of pediatric disease.

The Takeaway

This paper is a game-changer because it tells us:

1. Kids aren't just small adults: Their heart disease has a unique biological cause (reactivated developmental signals) that adults don't have.
2. The "Stiffness" is key: The heart is failing because it's too stiff, not because it's scarred.
3. New Treatments are possible: Instead of using adult heart failure drugs, we need to develop new medicines specifically designed to turn off these "childhood construction managers" (Notch and WNT) to help children's hearts relax and pump again.

In short: The heart of a sick child isn't broken by age or wear and tear; it's stuck in a loop of trying to grow. The cure isn't to patch the damage, but to help the heart finally "grow up" and stop acting like a baby.

Technical Summary

1. Problem Statement

Pediatric idiopathic dilated cardiomyopathy (iDCM) is a leading cause of cardiac-related mortality in children. Current therapeutic strategies rely on extrapolating Guideline-Directed Medical Therapy (GDMT) from adult heart failure, which has shown limited efficacy in children.

• Biological Discrepancy: Adult DCM is typically characterized by chronic metabolic impairment, mitochondrial dysfunction, and fibrotic signaling (e.g., TGF-β). In contrast, pediatric iDCM exhibits minimal fibrosis and hypertrophy but shows significant dysregulation of developmental signaling pathways, specifically Notch and WNT/β-catenin, which are normally quiescent in the postnatal heart.
• Knowledge Gap: While transcriptomic studies have identified the reactivation of these pathways in pediatric hearts, the mechanistic link between their co-activation and the specific pathological phenotype (ventricular dilation, stiffness, and dysfunction) remains unknown. Furthermore, the role of circulating factors like secreted frizzled-related protein-1 (sFRP1), which is elevated in pediatric patients, has not been fully elucidated in a causal model.

2. Methodology

The study employed a multi-modal approach combining human tissue analysis, in vitro cell models, and a novel in vivo juvenile rat model.

• Human Samples: Left ventricular (LV) tissue was obtained from pediatric iDCM patients (transplant candidates) and adult iDCM patients, compared against non-failing (NF) donor controls.
• In Vitro Model: Neonatal Rat Ventricular Myocytes (NRVMs) were treated with:
  • Isoproterenol (ISO) to mimic elevated catecholamines.
  • Recombinant sFRP1 (a WNT modulator).
  • Combined ISO + sFRP1 treatment.
  • Intervention: siRNA knockdown of CTNNB1 (β-catenin) and pharmacological inhibition of Notch using DAPT (a γ-secretase inhibitor).
• In Vivo Model: A juvenile Sprague-Dawley rat model was developed. Rats received intraperitoneal injections of ISO, sFRP1, or the combination (ISO+sFRP1) for 14 days.
  • Assessments: Echocardiography (EF, volumes, wall thickness), Atomic Force Microscopy (AFM) for myocardial stiffness, histology (fibrosis/hypertrophy), and molecular profiling.
• Omics & Analysis:
  • Bulk RNA-seq: To identify differentially expressed genes (DEGs) and pathway enrichment.
  • Single-nucleus RNA-seq (snRNA-seq): To resolve cell-type-specific transcriptional changes and intercellular communication networks (using CellChat).
  • Protein Analysis: Immunoblotting for NICD (Notch Intracellular Domain) and β-catenin in cytoplasmic and nuclear fractions.

3. Key Contributions

1. Novel Disease Model: Development of a juvenile rat model that recapitulates the unique pediatric iDCM phenotype (dilation, stiffness, fetal gene reactivation) without the fibrosis or hypertrophy typical of adult DCM.
2. Mechanistic Insight: Identification of a synergistic co-activation of Notch and WNT/β-catenin pathways as the driver of pediatric iDCM, distinct from adult pathology.
3. Stiffness Mechanism: Demonstration that increased myocardial stiffness in pediatric iDCM occurs independently of fibrosis, likely driven by cytoskeletal or ECM proteoglycan remodeling mediated by these pathways.
4. Therapeutic Validation: Proof-of-concept that inhibiting Notch signaling (via DAPT) reverses pathological remodeling, improves cardiac function, and normalizes myocardial stiffness in vivo.

4. Key Results

Human Tissue Analysis

• Pediatric vs. Adult: Pediatric iDCM hearts showed significant accumulation of NICD (active Notch) and β-catenin in both cytoplasmic and nuclear fractions. Adult iDCM hearts did not exhibit this activation.
• sFRP1 Levels: Elevated sFRP1 was confirmed in pediatric patient sera and hearts, correlating with disease severity.

In Vitro Findings (NRVMs)

• Synergy: ISO alone or sFRP1 alone induced mild changes, but the combined treatment (ISO+sFRP1) synergistically activated the Fetal Gene Program (FGP), upregulated NPPA/NPPB, and decreased the MYH6/MYH7 ratio.
• Pathway Activation: Combined treatment significantly increased NICD and β-catenin levels.
• Crosstalk: Silencing CTNNB1 (β-catenin) prevented the activation of Notch target genes (HEY1, HEY2, HES1) and the FGP, indicating β-catenin acts upstream or in concert to drive Notch activation. Conversely, Notch inhibition (DAPT) reduced β-catenin accumulation.

In Vivo Findings (Juvenile Rat Model)

• Phenotype: ISO+sFRP1 treated rats developed:
  • Significant reduction in Ejection Fraction (EF).
  • Left ventricular dilation (increased LVID and LV volume).
  • 2-fold increase in myocardial stiffness (measured by AFM).
  • Absence of fibrosis or myocyte hypertrophy, mirroring human pediatric data.
• Transcriptomics:
  • Bulk RNA-seq showed 96% overlap in DEGs between the rat model and human pediatric DCM hearts.
  • snRNA-seq revealed an expansion of a specific ventricular cardiomyocyte subcluster (Cluster 2) with enriched Notch signaling and predicted CTNNB1 regulation.
  • Signaling Paradox: While global intercellular communication (CellChat) was reduced (fewer ligand-receptor interactions), intracellular Notch signaling was hyper-activated, suggesting ligand-independent activation driven by stress.
• Therapeutic Intervention: Treatment with DAPT (Notch inhibitor) in ISO+sFRP1 rats:
  • Prevented the reduction in EF.
  • Abrogated the increase in myocardial stiffness.
  • Normalized β-catenin levels and FGP reactivation.

5. Significance and Conclusion

• Paradigm Shift: The study establishes that pediatric iDCM is a biologically distinct entity driven by the reactivation of developmental signaling axes (Notch-WNT), rather than the fibrotic mechanisms seen in adults.
• Mechanism of Stiffness: It uncovers a novel mechanism where developmental signaling drives myocardial stiffening independent of fibrosis, explaining the poor response to standard adult therapies.
• Therapeutic Implications: The findings support the development of age-specific therapies. Inhibiting the Notch-WNT axis (specifically downstream effectors) offers a promising strategy to prevent maladaptive remodeling and improve function in children with iDCM, moving away from the "one-size-fits-all" adult approach.
• Future Directions: The study highlights the need to investigate the specific cytoskeletal or proteoglycan modifications causing stiffness and to refine therapeutic targets to avoid systemic side effects of global Notch blockade.